menu
    • menu
    [{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Armistice Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Eravacycline","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tetraphase Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"Tetraphase Pharmaceuticals \/ Armistice Capital","highestDevelopmentStatusID":"12","companyTruncated":"Tetraphase Pharmaceuticals \/ Armistice Capital"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"AcelRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Eravacycline","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Tetraphase Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Tetraphase Pharmaceuticals \/ AcelRx Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Tetraphase Pharmaceuticals \/ AcelRx Pharmaceuticals"},{"orgOrder":0,"company":"Ewha Womans University ","sponsor":"SOM Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Eravacycline","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Ewha Womans University ","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Ewha Womans University \/ SOM Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Ewha Womans University \/ SOM Biotech"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Eravacycline","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tetraphase Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"Tetraphase Pharmaceuticals \/ Melinta Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Tetraphase Pharmaceuticals \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Eravacycline","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Tetraphase Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Tetraphase Pharmaceuticals \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Tetraphase Pharmaceuticals \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Eravacycline","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Not Applicable"},{"orgOrder":0,"company":"SOM Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Eravacycline","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SOM Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SOM Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"SOM Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Eravacycline","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Everest Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"TTY BIOPHARM CO LTD","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Eravacycline","moa":"30S Ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Everest Medicines \/ TTY Biopharm","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ TTY Biopharm"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Eravacycline","moa":"30S Ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Not Applicable"},{"orgOrder":0,"company":"La Jolla Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Eravacycline","moa":"30S Ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"La Jolla Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"La Jolla Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"La Jolla Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Eravacycline","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Pharma Group","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Eravacycline","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Shanghai Pharma Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Pharma Group \/ Everest Medicines","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Pharma Group \/ Everest Medicines"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Eravacycline","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Eravacycline","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Eravacycline

    Menu

    Eravacycline

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Everest Medicines

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Everest Medicines

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Everest Medicines Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal In...

                            Details : Xerava (eravacycline) is a novel, fully synthetic, fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant ("MDR") isolates.

                            Brand Name : Xerava

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 27, 2023

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Everest Medicines

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Everest Medicines

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Everest Medicines Announces Commercial Launch and First Prescription for XERAVA in China

                            Details : XERAVA® (eravacycline) is a novel, fully synthetic, fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant ("MDR") isolates.

                            Brand Name : Xerava

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 27, 2023

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Shanghai Pharma Group

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Shanghai Pharma Group

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Everest Medicines

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Everest Medicines Announces Strategic Partnership with Shanghai Pharma Subsidiary to Accelerate the Commercial...

                            Details : Under the partnership, Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA (eravacycline), a novel, fully synthetic, fluorocycline intravenous antibiotic, in China.

                            Brand Name : Xerava

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 18, 2023

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Everest Medicines

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Everest Medicines

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Everest Medicines

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Everest Medicines Announces Approval of Xerava in China for the Treatment of Complicated Intra-Abdominal Infec...

                            Details : Xerava (eravacycline) is bacteriostatic which disrupts bacterial protein synthesis by binding to the 30S ribosomal subunit thus preventing the incorporation of amino acid residues into elongating peptide chains.

                            Brand Name : Xerava

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 16, 2023

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            La Jolla Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            La Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) ...

                            Details : XERAVA® (eravacycline) for injection is approved by the U.S. Food and Drug Administration (FDA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older.

                            Brand Name : Xerava

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 14, 2022

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Everest Medicines

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Everest Medicines

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Everest Medicines Announces Approval of XERAVA® in Hong Kong for the Treatment of Complicated Intra-Abdominal...

                            Details : XERAVA® (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline, parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative and Gram-positive pathogens that have acquired MDR and are pr...

                            Brand Name : Xerava

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 08, 2022

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Everest Medicines

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Everest Medicines

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : TTY BIOPHARM CO LTD

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava in Taiwan

                            Details : Xerava™ (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline, parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative and Gram-positive pathogens that have acquired multidrug res...

                            Brand Name : Xerava

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 11, 2022

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : TTY BIOPHARM CO LTD

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Everest Medicines

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Everest Medicines

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Everest Medicines Receives CTA Approval by China NMPA for Phase 3 Trial of Xeravanfor for Community-Acquired B...

                            Details : Xerava (eravacycline) is a novel, fully synthetic, broad-spectrum parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative and Gram-positive pathogens that have acquired multidrug resistance (MDR) and a...

                            Brand Name : Xerava

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 05, 2021

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            SOM Biotech

                            Spain arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            SOM Biotech

                            Spain arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SOM Biotech Announces Poster Presentation on the Repurposing of Eravacycline for the Treatment of SARS-CoV-2

                            Details : In vitro experiments confirmed inhibition of the protease with an IC50 in the low micromolar range. Eravacycline inhibits the infection of SARS-CoV-2 in VeroE6 cells and shows no toxicity when applied alone.

                            Brand Name : TP-434

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 19, 2020

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Everest Medicines

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Everest Medicines

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Everest Medicines Completes Enrollment of Phase 3 Clinical Trial of Xerava™ to Treat Complicated Intra-Abdom...

                            Details : Everest Medicines ompleted patient enrollment for its Phase 3 clinical trial of eravacycline (marketed as Xerava™ in the US and EU) for the treatment of complicated intra-abdominal infections (cIAI) in patients in China.

                            Brand Name : Xerava

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 28, 2020

                            Lead Product(s) : Eravacycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth